{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-038473","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.986662+00:00","generated_at":"2026-06-06T00:09:23.162249+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Larimar Therapeutics closes $161.8M public offering of 19.7M shares at $8.74","bullets":["Offered 17,162,472 shares plus 2,574,370 option shares exercised immediately.","Net proceeds ~$161.8M after underwriting discounts and estimated expenses.","Joint bookrunners: Leerink Partners, Citigroup, Guggenheim Securities.","All shares sold by company; offering closed February 16, 2024.","Proceeds will support clinical development of nomlabofusp (CTI-1601) and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-038473","json":"https://secwatch.observer/filing/0001193125-24-038473.json","markdown":"https://secwatch.observer/filing/0001193125-24-038473.md","text":"https://secwatch.observer/filing/0001193125-24-038473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/0001193125-24-038473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/d780024d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:09:23.162249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4541666ef3c892446553bd3d2a0ad75181eb0f68","claim":"Larimar Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein valued at approximately $161.8 million (effective 2024-02-14).","evidence_excerpt":"On February 14, 2024, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 17,162,472 shares (the “ Shares ”) of the common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $8.74 per share, less the underwriting discounts and commissions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312524038473/0001193125-24-038473-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein"},{"label":"Value","value":"approximately $161.8 million"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}